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ABSTRACT 
Serum albumin is the major protein of the mammalian blood 
circulation Apart from its involvement in the maintenance blood 
pH and osmotic pressure, it is chiefly responsible for the transport 
of various compounds both exogenous and endogenous in nature 
to different tissues of the body. Among the physiological ligands 
transported by albumin, bilirubin and fatty acids are more important. 
On the other hand, drugs constitute the major class of exogeneousligands 
which are also transported by albumin.Considering the total number 
of ligands bound to albumin, it is inconceivable to think of the 
same number of ligand binding sites on albumin molecule. Therefore, 
it seems that same binding sites are shared by several compounds. 
Thus, it is possible that some ligands may be displaced from albumin 
in the presence of other ligands.Binding of bilirubin to albumin is 
physiologically important since increase in the free bilirubin con-
centration in the blood may lead to the development of various disorders 
such as kemicterus in infants and jaundice in adults. Various drugs 
are well known displacer of bilirubin from albumm. However, the 
displacement mechanisms( whether competitive or allosteric) of a 
large number of drugs are not known. In the present study, we have 
studied the binding of bilirubin and three drugs namely, indomethacin, 
chlorpromazine and oxyphenbutazone to serum albumins from three 
different sources namely, human, bovine and sheep under different 
conditions of pH and ionic strength. 
II 
Human and sheep serum albumins were isolated in homogeneous 
form from human and sheep sera respectively using a salt fractionation 
procedure.The three albumins were identical in various properties 
such as relative mobility in polyacrylamide gel electrophoresis, Ve/ 
Vo ratio on Sephacryl S-200HR column chromatography and fluo-
rescence excitation and emission maxima. When the interaction of 
bilirubin with these albumins was studied by visible absorption spec-
troscopy, all three albumins produced a red shift of 25nm in the 
absorption spectrum of bilirubin which was indicative of the binding 
of bilirubin to serum albumm. Upon quantitation of bilirubin binding 
in terms of percent difference spectral change at >.max (480nm), 
all three albumins showed similar binding. This may be due to the 
similar microenvironment in the bilirubin binding sites in all these 
albumins. In order to see the role of various non-covalent interactions 
in the binding of bilirubin to albumin, binding studies were made 
at different ionic strengths using visible difference absorption 
spectroscopy. In all cases bilirubin binding decreased on increasing 
the ionic strength. The decrease in bilirubin binding with the increase 
in ionic strength suggests the importance of electrostatic interactions 
in the binding process. The effect was more pronounced in BSA 
and SSA than in HSA. Further, when the effect of pH on bilirubm 
binding to three serum albumins was studied the binding remamed 
unaffected between pH 8.0 and 11.0 beyond which it decreased sharply 
presumably due to alkaline denaturation of albun)in. Taken into 
I l l 
consideration the role of electrostatic interactions and earlier results 
on the involvement of lysine residues in this interaction, our binding 
data at different pH values suggests that the critical lysine residue(s) 
in all three albumins must be having abnormally high pK value.Bilirubin 
binding to these albumins was also studied by fluorescence quenching 
technique as the addition of bilirubin to these albumins caused significant 
quenching in the emission spectra of albumins. Fluorescence quenching 
studies with all the three albumins showed similar kind of bilirubin 
binding pattern. All these results suggest that three albumins are 
indistinguishable from each other in terms of bilirubin binding. 
The three drugs used in this study( indomethacin, chlorpromazine 
and oxyphenbutazone) also produced significant quenching in the 
emission spectra of albumins which was suggestive of the binding 
of these drugs to these albumins. In order to study the role of various 
non-covalent interactions, binding was studied at different ionic strengths 
in the range of 0.02 to 1.0. In case of indomethacin, a decrease 
in binding was observed on increasing the ionic strength, suggesting 
the involvement of electrostatic interactions in this binding. On the 
other hand , significant increase in binding was noticed on increasing 
the ionic strength in the case of chlorpromazine and oxyphenbutazone 
which was suggestive of the importance of hydrophobic interactions 
in the binding of these drugs to albumins. The extent of binding 
of these drugs was more pronounced in case of BSA compared 
to SSA. A comparison of the binding results of indomethacin to 
that of bilirubin-albumin interaction in terms of the involvement of 
IV 
electrostatic interactions suggests that these ligands bind to albumin 
in a similar manner. These results were in good agreement with the 
previous results on the sharing of the same binding site by these 
ligands. Binding results of two other drugs (chlorpromazine and 
oxyphenbutazone) and their comparison with bilirubin-albumin 
interaction suggest that these drugs bind at a site different from 
bilirubin binding site In view of the known bilirubin displacing effect 
of chlorpromazine, it can be said that the drug displaces bilirubin 
probably in a non-competitive or allosteric manner. Further studies 
are required to prove this conclusion. 
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ABSTRACT 
Serum albumin is the major protein of the mammahan blood 
circulation. Apart from its involvement in the maintenance blood 
pH and osmotic pressure, it is chiefly responsible for the transport 
of various compounds both exogenous and endogenous in nature 
to different tissues of the body. Among the physiological ligands 
transported by albumin, bilirubin and fatty acids are more important. 
On the other hand, drugs constitute the major class of exogeneousligands 
which are also transported by albumin.Considering the total number 
of ligands bound to albumin, it is inconceivable to think of the 
same number of ligand binding sites on albumin molecule. Therefore, 
it seems that same binding sites are shared by several compounds. 
Thus, it is possible that some ligands may be displaced from albumin 
in the presence of other ligands. Binding of bilirubin to albumin is 
physiologically important since increase in the free bilirubin con-
centration in the blood may lead to the development of various disorders 
such as kemicterus in infants and jaundice in adults. Various drugs 
are well known displacer of bilirubin from albumin. However, the 
displacement mechanisms( whether competitive or allosteric) of a 
large number of drugs are not known. In the present study, we have 
studied the binding of bilirubin and three drugs namely, indomethacin, 
chlorpromazine and oxyphenbutazone to serum albumins from three 
different sources namely, human, bovine and sheep under different 
conditions of pH and ionic strength. 
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of ligands bound to albumin, it is inconceivable to think of the 
same number of ligand binding sites on albumin molecule. Therefore, 
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displacement mechanisms( whether competitive or allosteric) of a 
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chlorpromazine and oxyphenbutazone to serum albumins from three 
different sources namely, human, bovine and sheep under different 
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I I 
Human and sheep serum albumins were isolated in homogeneous 
form from human and sheep sera respectively using a salt fractionation 
procedure.The three albumins were identical in various properties 
such as relative mobility in polyacrylamide gel electrophoresis, Ve/ 
Vo ratio on Sephacryl S-200HR column chromatography and fluo-
rescence excitation and emission maxima. When the interaction of 
bilirubin with these albumins was studied by visible absorption spec-
troscopy, all three albumins produced a red shift of 25nm in the 
absorption spectrum of bilirubin which was indicative of the binding 
of bilirubin to serum albumin. Upon quantitation of bilirubin binding 
in terms of percent difference spectral change at >,max (480nm), 
all three albumins showed similar binding. This may be due to the 
similar microenvironment in the bilirubin binding sites in all these 
albumins. In order to see the role of various non-covalent interactions 
in the binding of bilirubin to albumin, binding studies were made 
at different ionic strengths using visible difference absorption 
spectroscopy. In all cases bilirubin binding decreased on increasing 
the ionic strength. The decrease in bilirubin binding with the increase 
in ionic strength suggests the importance of electrostatic interactions 
in the binding process. The effect was more pronounced in BSA 
and SSA than in HSA. Further, when the effect of pH on bilirubin 
binding to three serum albumins was studied the binding remained 
unaffected between pH 8.0 and 11.0 beyond which it decreased sharply 
presumably due to alkaline denaturation of albun i^n. Taken into 
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consideration the role of electrostatic interactions and earlier results 
on the involvement of lysine residues in this interaction, our binding 
data at different pH values suggests that the critical lysine residue(s) 
in all three albumins must be having abnormally high pK value. Bilirubin 
binding to these albumins was also studied by fluorescence quenching 
technique as the addition of bilirubin to these albumins caused significant 
quenching in the emission spectra of albumins. Fluorescence quenching 
studies with all the three albumins showed similar kind of bilirubin 
binding pattern. All these results suggest that three albumins are 
indistinguishable from each other in terms of bilirubin binding. 
The three drugs used in this study( indomethacin, chlorpromazine 
and oxyphenbutazone) also produced significant quenching in the 
emission spectra of albumins which was suggestive of the binding 
of these drugs to these albumins. In order to study the role of various 
non-covalent interactions, binding was studied at different ionic strengths 
in the range of 0.02 to 1.0. In case of indomethacin, a decrease 
in binding was observed on increasing the ionic strength, suggesting 
the involvement of electrostatic interactions in this binding. On the 
other hand , significant increase in binding was noticed on increasing 
the ionic strength in the case of chlorpromazine and oxyphenbutazone 
which was suggestive of the importance of hydrophobic interactions 
in the binding of these drugs to albumins. The extent of binding 
of these drugs was more pronounced in case of BSA compared 
to SSA. A comparison of the binding results of indomethacin to 
that of bilirubin-albumin interaction in terms of the involvement of 
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electrostatic interactions suggests that these hgands bind to albumin 
in a similar manner. These results were in good agreement with the 
previous results on the sharing of the same binding site by these 
ligands. Binding results of two other drugs (chlorpromazine and 
oxyphenbutazone) and their comparison with bilirubin-albumin 
interaction suggest that these drugs bind at a site different from 
bilirubin binding site. In view of the known bilirubin displacing effect 
of chlorpromazine, it can be said that the drug displaces bilirubin 
probably in a non-competitive or allosteric manner. Further studies 
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General Characteristics 
Serum albumin is the main protein in the sera of reptiles, fish 
and higher animals ( Massat & Dessauer, 1968). It is one of the most 
studied proteins ofblood circulation and belongs to a multigene family 
of proteins that includes aFP(APP) and vitaminD or group specific 
component (GC) binding protein.lt has a blood concentration of ~ 
50mg/ml and is considered to be chiefly responsible for the maintenance 
of blood pH. Many of the important functions of serum albumin is 
its propensity to bind a wide variety of structurally diverse organic 
and inorganic compounds. Virtually any small molecular weight 
compound binds weakly or strongly with albumin which enters blood. 
Serum albumin is believed to function as a transport protein and also 
serves in regulating the blood levels of certain drugs and metabolites 
( King & Spencer ,1970). Albumin molecule adopts itself to the ligand, 
seems to be the property which explains its cosmopolitan tastes 
(Peters,1985;Kragh-Hansen,1990;Figgee/a/.,1991; Stamlere/^/.,1992; 
Sakai, 1995; Farruggia, 1995). Serum albumin is supposed to be the 
major contributor to the maintenance of circulating fluid within the 
vascular system through its osmotic effect(~ 80% osmotic pressure 
contribution). Serum albumin, as a model protein has been studied 
extensively with respect to its structure and functions(Peters, 1970, 
1975,1985,1992; He & Carter,]992; Yanagisawa, 1997) and several 
reviews were appeared (Foster, 1960,1977; Watson, 1990; Yap et al, 1978; 
Habeeb, 1979;Kragh-Hansen, 1981,1990;Finlayson, 1980; Alexander 
et fl/.,1982; Rottschild et fl/.,1988; Hessera & Mackay, 1989 ; 
Geisow,1992; Carter & Ho, 1994). 
Biosynthesis and degradation 
Serum albumin is synthesised in the liver in the form of pre-
proalbumin containing a leader sequence of 18 amino acid residues. 
The biosynthesis has been seen in intact animals ( Morgan & Peters, 
1971; Walker et al.,1973) as well as in isolated perfused liver from 
different animals( Rothschild, 1972; Chen & Redman, 1977). Albumin 
mRNA contains about 2080 base pairs . The translation of albumin 
RNA starts with a signal peptide of the type commonly found on proteins 
destined for secretion. The signal peptide directs the growing peptide 
chain through the membrane of the endoplasmic reticulum and is 
quickly cleaved off. Disulfide bonds join quickly with the appearance 
of two cystine bridge ( Peters & Davidson, 1982). The newly formed 
albumin use to be in the form of proalbumin within the secretory 
channels of the liver cells ( Judah et al.,]973; Urban et al.,\974). 
During secretion proalbumin is the chief form of albumin and it differs 
from albumin in having a basic haxapeptide extension attached to its 
N- terminal residue( Judah et al.,\973\ Quinn et al.,\975, Patterson 
& Geller, 1977; Peters 1977, 1985). Proalbumin migrates from the 
rough endoplasmic reticulum to golgi complex through smooth en-
doplasmic reticulum. The hexapeptide is just cleaved before the release 
of albumin from the cell. The released propeptide is broken down in 
the liver cells without any effect on albumin synthesis(Peters & 
Davidson, 1986) and its ligand binding properties. Albumin has a half 
life of ~19days and it disappears from plasma in a first order 
manner(Peters,1970; Rosenoer et al.,\911). Serum albumin is highly 
water soluble. Invitro experiments highly concentrated solutions of 
albumin are possible though it occurs at a concentration of 35mg/ml 
in serum. By a number of techniques the molecular weight has been 
determined and found to be in the range of 65,000 - 69,000 
( Baldwin,1957; Squire et ^/.,1968, Tanford,1968; Andrews,1970) 
which is in good agreement with molecular wight calculated (66,439) 
from amino acid composition( Brown & Shockley, 1982).From 
electrospray ionization mass spectrum of BSA, the molecular weight 
was found to be 66,465.8 ( Hirayama et al.,1990). The total number 
of amino acid residues in BSA was determined as 583 with the help 
of Frit-fast atom bombardment mass spectrometry/ liquid chromatog-
raphy/ automated Edman degradation and its average molecular weight 
was corrected to be 66,430.3( Hirayama et <2/., 1990).It resembles with 
many other globular proteins in its hydrodynamic properties and some 
of them are listed in Table I. The ultraviolet light absorption peak 
lies at 278.5 - 279nm. The excitation and emission maxima are at 
282nm and 340nm respectively and fluorescence is dominated by 
its tryptophan residues. Albumin is typical globular protein as it rotates 
polarized light and there is a strong negative cotton effect at 233nm. 
CD in the UV region shows minima at 209nm, 222nm and a strong 
maxima near 195nm. 
The shape of albumin molecule has been studied by many workers 
( Hunter,1966; Squire et a/.,1968; McMillan, 1974; Wright & Thomp-
son, 1975). Squire and his collegues have suggested that serum albumin 
is a prolate ellipsoid of revolution with its major and minor axes 
being 40 and 140A°, and an axial ratio of 3.5 based on their experiments 
and some other published work( Squire et a/., 1968; Champagne, 1957; 
Luzzati et al,\966, Chaterjee & Chaterjee,1965; Moser et al,1966). 
More recent studies further supported these dimensions( Bendedouch 
& Chen,1983; Feng et «/.,1988). Three domain model of BSA as 
proposed by Brown & Shockley (1982) was accepted as a conceptual 
model by large number of workers( Carter et a/., 1989; Carter & 
He, 1990). Wright & Thompson (1975) have refined these axes to 41 
X 140.9A°. Electron microscopy at pH 1.9 reveals a structure made 
up of three globules in a string( Slayter,1965) which is consistent with 
Table I 
Physico-chemical properties of bovine and human serum 
albumins 
Property 
Molecular weight 
From composition 
From physical data 
Sedimentation coefficient 
V , xlO" 
Diffusion coefficient 
D20., ^ 10' 
Partial specific volume(v^) 
Intrinsic viscosity,(^) 
Overall dimensions,A° 
Optical absorbance. 
279nm, Ig litre 
Estimated a-helix(%) 
p-structure(%) 
Bovine 
66,399^ 
66,7002 
4.52 
5.95 
0.733^ 
0.04r 
41.6 X 140.9« 
0.667'« 
55^2 
W 
Human 
66,438' 
69,0002 
4.6^ 
6.1'' 
0.7333 
0.042^ 
38.0x150.0^ 
0.531'' 
50'2 
16"* 
1. Peters(1992); 2.Squire et «/.,(1968); 3.CharIwood (1961); 4.0ncley 
et a/.(1947); 5.Wagner & Scheraga(1956);6.Hunter(1966); 
7.McMillan(1974);8.Wright &Thompson(1975); 9.Hughes(1954);10.Janatova 
et aL,(1968);ll.Edwards et a/.,(1969);12.Sjoholms & Ijungstedt (1973);13.Reed 
et a/.,(1975);14. Foster(1977). 
three domain structure of albumin. 
Heterogeneit> and conformational states 
Albumin molecule is synthesized as single polypeptide chain but 
usually shows heterogeneity during its life time. The genetic variations 
of albumin such as bisalbuminemia, polymorphism (Schell & 
Blumberg,1977; Tamoky,I980) and analbuminemia(Dammacco et 
al, 1980) are very rare. Heterogeneity may also occur because of protein-
protein association, ligand binding (Guilani et a/., 1981; Moehring 
et a/., 1983) and conformational isomerization. Fraglen(1974) has clas-
sified this heterogeneity as macroheterogeneity and microheterogeneity. 
Macroheterogeneity involves the formation of dimers, oligomers or 
more often the polymers of albumin(Finlayson et a/., 1960; Friedli & 
Kistlerl970; Barnes e/a/., 1974; Saifer & Palo,1969). Albumin dimers 
can arise by the formation of disulfide bonds between the lone sulfhydryl 
groups of two albumin molecules or by other unknown covalent in-
teractions (Janatova,1974). The microheterogeneity in albumin prepa-
rations may be due to the differences in the amount of bound ligands 
such as lipids, bilirubin and various metabolites and drugs( Foster, 1960; 
Peterson & Foster, 1965; McMenamy & Lee, 1967; Anderson, 1969; 
Valmet,1970). Further, the lone sulfhydryl group is believed to par-
ticipate in the formation of disulfide bonds with small molecular weight 
thiol compounds e.g. cysteine or glutathione (King, 1961). It is because 
of this fact that even highly purified albumin preparations yield 
sulfhydryl content in the range of 0.6-0.7(Hughes, 1954; Foster, 1960; 
Sogami et al, 1969). Another potential cause of heterogeneity in albumin 
preparations is conformational isomerization. 
Serum albumin molecule changes its conformation under a variety 
of circumtances such as change in pH of the medium ( Dzhfarov,1991; 
Oliveri & Craierich,1995; Bramontic,1996). It exits in its normal state 
(N form) between pH 5.0 and 7.0 but undergoes conformational changes 
with change in the pH of the medium. Between pH 4.0 - 4.5 discontinuation 
of curve is seen when a neutral albumin solution is titrated with 
hydrochloric acid. Towards acidic pH as 4.0, another namely, "F form" 
( fast moving form) is obtained which moves more rapidly upon gel 
electrophoresis at pH 3-4 than N form and is precipitated readily by 
3M potassium chloride ( Foster, 1960, 1977). This transition is known 
as N<->F transition and has been studied by several workers (Herskovits 
& Laskowski,1962, Tanford et a/., 1967; Hilak et a/., 1974; Foster, 1977, 
Khan& Salahuddin, 1984; Dzhfarov, 1991; Sadler & Tucker, 1993). This 
transition involves a decrease in helical content (Hilak et a/., 1974), 
increase in tyrosyl exposure ( Herkovits & Laskowski, 1962) and in-
crease in intrinsic viscosity ( Tanford et al.,\967). Another form " E" 
( Expanded form) is also obtained when pH is lowered upto 3.0. Albumin 
solution shows an increase in intrinsic viscosity and the hydrodynamic 
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axial ratio rises from 4.0 to 9.0 ( Harrington et al.,]956). The helical 
content falls from 45% to 35% when pH of the solution is increased 
to 9.0, another form called "B"( Basic) form is obtained and the transition 
is called as N -> B transition. This B form migrates slowly towards 
anode on gel and has a helical content of 48%). It is reported that during 
N->B transition affinity for ligands increases. However N ->B transition 
is not as steep as N ^ F transition ( Leonard et a/., 1963; Zurawski & 
Foster, 1974, Dzhfarov,1991). Treatment of albumin above pH 9.0 for 
a period of 3 - 4 days results in its conversion into another form termed 
as "A" (aged) and is charactenzed by a slower migration rate on 
electrophoresis and decreased solubility in 3M potassium chloride 
(Nikkei & Foster, 1971). It is presumed that this reaction occurs due 
to the disulfide interchange involving the lone sulfhydryl group of 
albumin. 
Amino acid composition and structural origin 
It is widely believed that albumin molecule evolved from a protein 
of about 77amino acid residues by four fold tandem gene duplication 
and one deletion (Brown, 1976; McLachlan & Walker, 1977). The single 
thiol group is at residue 34 in a portion of chain which is not restrained 
by disulfide bonds. The two tryptophans of BSA are at residues 134 
and 212. The distribution of some other amino acid residues is uneven. 
giving distinct characteristics to different portions of albumin molecule. 
Asparagine and glutamine occur more frequently near the ends than 
in the middle. Tyrosine is heavily concentrated in loops 3 and 6 and 
the prolines occur at the tip of each large loop. The albumin molecule 
is not uniformly charged along its length. The domain I, Hand III of 
BSA have a net charge of -10, -8 and 0 respectively at pH 7.0. 
The knowledge of the structural features of each double loop is 
the key to understand the tertiary structure of the whole albumin 
molecule which consists of a repeating structure of these loops. 
Brown(1978) made an observation that the occurrence of invariant 
proline residues in the middle of the sequence enclosed by a disulfide 
bond in all the large loops. It was proposed that the sequence enclosed 
by disulfide bond in a large loop primarily contains a-helical structure 
and that its continuation is broken by the presence of invariant proline. 
Thus each large loop may be considered to be composedof two a-helical 
structures of about 22 amino acid residues which are joined by a hairpin 
like structure at the tip of the loop. In addition to the two helical structures 
described ; the segment joining the large loop to the small loop plus 
a portion of small loop is also proposed to exist in the form of a helical 
structure of about the same size as the two helices proposed in the 
large loop. This gives a prominent three helix structural organization 
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in each subdomain. The three helices can be put together to form a 
trough like structure with clear cut inside and outside. If the two 
subdomains are paired with hydrophobic forces together, they will 
produce cylindrical structures with a hydrophobic interior. This sort 
of arrangement is believed to create some of the important ligand 
binding sites in albumin. 
Amino acid composition of albumin from different species such 
as bovine, human,sheep, rat , dog , monkey, rabbit and frog has been 
worked out ( Peters, 1970,1985; Wallace & Wilson,1972; Maclaren & 
Patras,1976). The amino acid compositions of species i.e.human, 
bovine,sheep and rat are shown in Table II. Human and bovine serum 
albumins contain 585 and 583 amino acid residues respectively present 
in a single polypeptide chain( Thompson,1958; Hunter & 
McDufifie, 1959).The protein contains a higher number of acidic amino 
acid residues than basic ones,giving it a net negative charge of -15 
and -17 at neutral pH and acidic character to these albumins . The 
primary structures of bovine and human serum albumin have been 
determined by Brown and coworkers( Brown, 1975; Meloun et al, 1975) 
and is shown in Fig. 1. The sequences of albumin from various sources 
have been screened up and were found to have a high degree of 
homology. 
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Table II 
Amino acid composition of serum albumins of various 
Species 
Amino acid 
Alanine 
Arginine 
Asparagine 
Aspartic acid 
1/2-Cystine 
Glutamic acid 
Glutamine 
Glycine 
Histidine 
Isoleucine 
Leucine 
Lysine 
Methionine 
Phenylalanine 
Proline 
Serine 
Threonine 
Tryptophan 
Tyrosine 
Valine 
Total calculated 
Human 
62 
24 
17 
36 
35 
62 
20 
12 
16 
08 
61 
59 
06 
31 
24 
24 
28 
01 
18 
41 
585 
Bovine 
47 
23 
14 
40 
35 
59 
20 
16 
17 
14 
61 
59 
04 
27 
28 
28 
33 
02 
20 
36 
583 
Ovine 
50 
22 
14 
44 
35 
57 
19 
17 
18 
13 
63 
58 
04 
28 
28 
25 
30 
02 
20 
36 
583 
Rat 
61 
24 
20 
32 
35 
57 
25 
17 
15 
13 
56 
53 
06 
26 
30 
23 
34 
01 
21 
35 
584 
Met charge at pH 7 -15 -17 -21 -12 
12 
o 
o I 
t 
s 
z 
< 
z 
o 
o i 
t 
^ 
L3 
L4 
LS 
L€ 
L7 
L8 
Fig. 1. Primary structure of serum albumin Positions of domains 
(I, n and ni) and loops (L1-L9) are shown. 
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The serum albumin is organised in three structural homologous 
domains (-20%) of nearly equal size. Their positions m the primary 
sequence of these albumins are : Domain 1(1-190), Domain 11(191-
382) and Domain 111(383-583/585) .During the late seventies, Brown 
proposed that each domain was a product of 3 subdomains (two large 
and one small) held together by disulfide bonds except the first large 
double loop. This organization of total 6 large and 3 small subdomains 
came to an end recently . An American scientist Daniel C.Carter 
determined atomic structure of HSA by X- ray crystallography to a 
resolution of 2.8A°. He showed that each domain is a product of 2 
subdomains that posses a common structural motif Thus six subdomains 
( lA/ IB, 2A/2B ) assemble to form a heart shaped molecule rather 
than cigar shapedAJ shaped as earlier proposed . There are 10 principal 
helices in each domain ( hj - h^ )^, and subdomain A and B share a 
common motif that includes h./hj h7 h./ h7 h, for subdomain A and 
1 2 3 4 5 0 
h^ /hg/ hg and h,Q for subdomain B.The principal portion of each 
subdomain is formed by one of the six large disulfide loops often referred 
as 1/3/4/6/7 and 9. Three of these loops l,4,and 7 are supplemented 
by additional but smaller disulfide loops (2/ 5/ 8). Combination of loops 
1/2/4/5/7/8 represents 3 A subdomains, lA/ IIA/ III A and 3/6/9, B 
subdomains, IB/IIB/ IIIB. Two larger helices in stucture occur at 
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interdomain connection ( IB - IIA/ IIB - IIIA). Thus the total number 
of hehces are 28 rather 30. 
Secondary structure analysis gives high helical content in serum 
albumins. The optical rotation and circular dichroism studies suggest 
55% helical content and 16% p-pleated sheet ( Sjoholm & 
Ljungstedt,1973; Reed et al, 1975 ; Foster,1977; Takada et al.,\99\. 
The tertiary structure within a domain is formed by the spatial arrange-
ment of large and small loops to form a somewhat cylindrical structure 
containing a distinct hydrophobic and hydrophilic region. 
The crystal structure ( three dimensional structure ) of albumin 
has been worked out by Carter & Ho, 1994 which reveals a heart shaped 
molecule approximated to an equilateral triangle with sides of ~80A" 
and a depth of i) ~30A^ rather than prolate ellipsoid as predicted earlier 
based on physical properties. The values determined from the crystal 
structure ( Carter & Ho, 1994) agree well with the various properties 
such as axial ratio, radius of gyration, distances between various amino 
acid residues and secondary structure as obtained earlier by various 
techniques ( Moser et a/., 1966; Cannistraro & Sacchetti,1986; Hagag 
et a/., 1983; McLachlan & Walker, 1977; Sjoholm & Ljungstedt,1973). 
Furhter, Cys-34 is not in close proximity to any disulfide , thus making 
its participation difficult in disulfide interchange reaction. Contrary 
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to the asymmetric charge distribution based on primary structure, 
distribution seems fairly uniform without any significant pattern of basic 
versus acidic residues. 
Ligand - binding properties 
Albumin binds reversibly to an incredible variety of ligands and 
thus behaves as unique universal carrier( Peters, 1970,1975,1985,1992; 
Kragh-Hansen, 1990,1996; Figge et a/. 1991; Carter & Ho, 1994; Sakai, 
1995; Nerti,1995; Takamora, 1996; Vorum,1996; Nazaraki, 1997; 
Hewns,1997) having multiple and adaptable binding sites 
( Brodersen,1979 ). Binding of these compounds to serum albumin 
is important in: i) preventing their removal from blood circulation into 
urine, ii)making them nontoxic and iii) making poorly soluble 
compounds soluble in the aqueous medium. Other than physiologically 
important ligands like fatty acids, bilirubin and so on, a broad spectrum 
of drugs also bind to albumin upon their entry into blood circulation. 
Electrostatic interaction is one of the important noncovalent interactions 
which are involved in binding of these compounds to albumin. The 
binding of bilirubin and fatty acids to serum albumins has been studied 
indetail ( Brodersen,1974; Brodersen & Ebbesen,1983; Tayyab & 
Qasim, 1987,1989; Mir et al.,1992) . Some of the drugs which bind 
to albumin are ampicillin, warfarin, digitoxin, diazepam, phenytoxin 
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( Kober et ^ /.,1980), indomethacin ( Shankaran et a/., 1982; Brodersen 
,1983) , diclophenac, flurbiprofen, diflunisal, phenylbutazone 
( Brodersen, 1983; Brandys & Negrusz,1987), sulfobromopthalein, 
ethacrynic acid, hypolipidemic agents( Meijera & Sluijs,1987), 
doxacilin,dicloxacilin and flucloxacillin (Kucers «& McK Bennet,1979; 
Friedman & lewis,1980, Walker,1987), lorazepam (Honore et a/.,1983; 
Walker, 1987), salycilic acid and chlorpromazine ( Trivedi et al.,-
unpublished work). Some other workers have also studied the inter-
action of various drugs with albumin ( Robertson et al,\99\, Onks 
et al.,\99\, Evans et al, 1992; Broers et a/.,1993; Aubry et a/.,1995; 
Epps etal, 1995; Forgaes & Cserhati, 1995; Hage, 1995; Nowak, 1995; 
Zafan, 1995; Ecknhofif, 1996, Vorum, 1996; Cheruvallath, 1997; Fleury, 
1997; Mosely, 1997; Vorum, 1997; Yanagisawa, 1997; Quaglia, 1997; 
Nerli, 1997). Various attempts have been made to study the binding 
of these compounds at molecular level and it has been demonstrated 
that three high affinity binding sites on albumin namely warfarin, the 
diazepam and the digitoxin binding sites exist on albumin molecule, 
these sites are also expressed as sitel, sitell, and siteIII( Broderson 
et a/.,1977; Muller & Wollert,1979; Sjoholm et a/.,1979; Fehske et 
al.,1979, 1981; Bree et a/.,1993; Young,1993). Many organic dyes like 
methyl red (Burkhard et a/., 1961, phenol red (Rodkey, 1961), bomocresol 
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green( RodkeyJ964), bromophenol blue ( Bjerrum,1968; Tayyab & 
Qasim,1990), congo red( Peters, 1970, Tayyab & Qasim,1990) etc. 
also bind to serum albumin . In addition to a variety of organic 
compounds, albumin also binds a number of metal ions which include 
Ca^, Cu'\ W\ Zn'Mn^\ Co^\Cd^\ng'^ and AF^ ( Sarkar,1983; 
Trapp,1983; Goumakos et a/., 1991; Masuoka et al.,1993, Masuoka 
& Saltman,1994; Bal et a/.,1994; Zhou et a/.,1994; Vorum et al.,1995). 
Other biologically important compounds interacting with albumin are 
tryptophan ( Fuller & Roush,1973; Cannigham et a/., 1975), steroid 
hormones ( Romeu et a/., 1975; Bassett et a/., 1977), bile acids ( Anwar 
el al,\976, Grabowski et a/., 1976), tyrosine and cortesol etc. 
The fatty acid and bilirubin binding sites are most extensively studied 
as these are the physiologically important ligands and are transported 
in the blood in the form of complexes with albumin. Circulating albumin 
carries 0.5 - 2.0 mole of fatty acids per mole of albumin, although 
invitro albumin has been demonstrated to be capable of binding as 
many as 6 moles of stearate, 7 moles of palmitate and 8 moles of 
oleate (Spector, 1965). Recent studies with BSA using affmity labelling 
and nuclear magnetic resonance spectroscopy ( Reed, 1986; Cestota 
et al., 1987) have established the presence of two strong binding sites 
in COOH terminal half of albumin and a somewhat weaker site in the 
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NHj terminal half. A lot of progress has been made in the study of 
binding sites with the help of affinity labelling , competitive binding, 
modification technique, fragmentation of albumin, interaction between 
one ligand site and other by computing distance, using energy transfer, 
genetically point mutation or by using genetic variants differing in 
specificity of binding for a particular ligand and most recently with 
the X-ray cystallographic approach. 
Bilirubin - albumin interaction 
Free bilirubin is cytotoxic and neurotoxic. However most of the 
bilirubin binds to albumin in serum and becomes nontoxic which 
transports it to the liver for subsequent conjugation and excretion. Various 
ligands such as drugs and fatty acids are reported to displace bilirubin 
from albumin, leading to increase in the level of bilirubin in plasma. 
Under physiological condition, the primary binding site is not saturated 
bacause of low concentration of bilirubin but in jaundiced neonates, 
the primary binding site is saturated and the bilirubin enters into central 
nervous system causing Kemicterus( Broderson, 1979).Thus, it is as-
sumed that an insignificant role in detoxification of bilirubin is played 
by second and third binding sites( Jacobson, 1972,1975,1976,1978; 
Reed et.al.,1975;Geisow and Beaven,l977; Sjodinet.al.,1977; Kuenzle 
etal., 1976, 1977). It is to be noted that fragmentation studies , affmity 
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labelling and chemical modification tehniques were used to understand 
the mechanism involved in albumin-bilirubin interaction.The interac-
tion of bilirubin with various proteolytic fragments of BSA was carried 
out by Reed et.al.(1975) in order to localize the site of bilirubin on 
albumin . Out of twelve fragments only three P-13( 1-306), P-44( 1-
385) and P-14( 186-306) were able to interact with bilirubin.lt was 
proposed that primary bilirubin binding site lies close to N-terminal 
of domainll bacause 186-238 sequence is common in all the three 
fragments which bind bilirubin. 
The role of amino acid residues in bilirubin binding was inves-
tigated by several chemical modification studies. Jacobson (1972) 
proposed that arginine, lysine, histidine and tyrosine may be important 
in this interaction at the primary binding site. Later, Jacobsen( 1976) 
showed the involvement of lysine residue in this interaction. A novel 
approach of covalent coupling of bilirubin to primary binding site was 
used by Jacobsen (1978) to couple reactive lysine with bilirubin. On 
the basis of his results, Jacobsen proposed Lys-240 in HSA and Lys-
238 in BSA to be the critical lysine residue. Due to some disagreement 
about the position of critical lysine residue, it was proposed by some 
other workers as Lys-220 and Lys-195 for HSA and BSA respectively 
as critical lysine residue. The earlier prediction of Lys-240 was ruled 
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out by studies with herbon variant of albumin( a genetic variant with 
Lys240^Glu).Studies from our laboratory have pointed towards the 
direction with the involvement of buried lysine residues in this in-
teraction. It is generally believed that one or two lysine residues are 
involved in bilirubin-albumin interaction in spite of certain uncertain-
ties regarding the identity of lysine residue(s). The evidence for the 
above mentioned studies is derived from ionic strength and temperature 
dependence of this interaction. Jacobsen (1977) suggested that binding 
of bilirubin at primary binding site is driven by strong enthalpic forces 
and not by hydrophobic interactions as with the increase in ionic 
strength and temperature the affinity for binding is not increased. These 
reports are consistent with the results of Brodersen (1979b) who 
performed detailed studies on the solubility of bilirubin and found 
that bilirubin has a poor solubility in apolar solvents. The low solubility 
of bilirubin in aqueous solutions was attributed to the intramolecular 
hydrogen bonding in this ligand, leaving no polar groups available 
for interaction with water molecules. Geometrical changes take place 
in bilirubin molecule involving rotation of the dipyrrole halves of the 
molecule when bilirubin binds at the primary binding site in albumin. 
Jacobsen & Brodersen(1983) proposed that the bilirubin molecule 
exists in a more expanded conformation at its binding site. The normal 
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hydrogen bonded pattern is lost(Lightner et a/., 1986) and probably 
the two negative charges contributed by carboxyl groups of bilirubin 
are neutralized by two positive charged groups of albumin. 
Jacobsen & Brodersen (1983) studied the idnetics of interaction 
of bilirubin, xanthobilirubin and mesobilirubin with albumin and pro-
posed that this interaction is biphasic involving a fast step followed 
by slow relaxational changes which lost for a period of about SOOsec. 
In the second phase, several conformational changes are believed to 
occur in albumin molecule involving rotation of one half domain of 
albumin, binding one pyrrole ring of bilirubin relative to the another 
half domain to which second chromophore of bilirubin is bound. Such 
conformational changes have also been observed by Honore(1987). 
The bilirubin binding site has been proposed to be located between 
subdomains IC and 2AB(Brodersen, 1979a) which would involve the 
rotation of these subdomains relative to each other. This rotation fixes 
the two halves of bilirubin dianion at a specific dihedral angle resulting 
in change of exciton splitting and the chirality of bilirubin molecule 
. The later is responsible for the strong cotton effect seen in bilirubin-
albumin complex at pH 8.0 (Hermatz & Blauer,1975). On this basis, 
it appears that probably bilirubin binds "loosely" at the surface of the 
protein near the primary binding site which may be followed by opening 
22 
a hydrophobic pocket in which the bihrubin molecule slides and reaches 
its primary binding site in the protein interior ( Tayyab & Qasim,1987). 
From the three dimensional structure of albumin, specialized 
cavities in subdomains IIA and IIIA have been identified as sites for 
small heterocyclic and aromatic carboxylic acids( He & Carter, 1992) 
and are consistent with site I (hydrophobic pocket in subdomain IIA) 
and sitell( pocket with subdomain IIIA) proposed earlier ( Sudlow et 
a/., 1976). Primary binding activity appears to reside in subdomain IIIA 
whereas subdomain IIA is more specialized (He & Carter, 1992). Brown 
& Shockley(1982) proposed that long chain fatty acid binding sites 
reside in B subdomains. Bilirubin site is believed to reside in subdomain 
IIA( Carter & Ho, 1994). 
To understand structure function relationship, catalytic properties 
and ligand binding characteristics of proteins, chemical modification 
technique has widely been used (Glazer,1970; Glazer et al.,1975; 
Means & Feeney,1971; Stark, 1970; Habeeb,1971; Spande et al., 1970). 
Extensive acylation of lysine residues of proteins have been performed 
earlier with an aim to understand the influence of such modifications 
on physiochemical and biological properties of proteins( Habeeb & 
Atassi,1970; Janas & Weber, 1970; Nakagawa et a/., 1972; Khan & 
Surolia,1982; Ansari et al.,1975; Tayyab & Qasim,1986). Previous 
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Studies of succinylation of BSA from this laboratory (Tayyab & 
Qasim,]986) suggested that BSA contains about 50% exposed , 37% 
partially exposed and 13% buried(inaccessible) lysine residues which 
could not be succinylated. None of the exposed and partially exposed 
lysines were implicated in bilirubin binding. It was suggested that one 
or two of the buried lysine (about 8 residues) may be involved in the 
albumin-bilirubin interaction( Tayyab & Qasim, 1987).Drugs which 
displaced bilirubin from albumin are believed to act either in a com-
petitive or noncompetitive manner, characterization of drug binding 
sites is therefore essential in order to understand the mode of their 
binding and displacing action. 
In this thesis, interaction of several ligands, namely, bilirubin, 
indomethacin, chlorpromazine and oxyphenbutazone with different 
serum albumins ( BSA, HSA and SSA ) has been studied. The in-
teraction studies are carried under different conditions of pH and ionic 
strength. The results obtained with SSA are compared with the results 
of bovine and human serum albumins. 
oi 
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A. MATERIALS 
1.Proteins and drugs 
Bovine serum albumin BSA fraction V( Lot No. 0140105) was 
purchased from Sisco Research Laboratories Pvt. Ltd., India. Sheep 
and human serum albumins(SSA and HSA) were prepared according 
to the method of Tayyab & Qasim (1990) and used as such throughout 
these studies. Drugs, namely, indomethacin ( Lot No. 60H0448), 
chlorpromazine ( Lot No. 112H0125) and oxyphenyl butazone (Lot 
No. 64F 00601) were product of Sigma Chemical Company, USA. 
2. Gel chromatographic media 
Sephadex G-200 was purchased from Pharmacia Fine Chemicals, 
Sweden. Sephacryl S-200HR (Lot No. 63F-0380) with a bed diameter 
of 40-105^1 was obtained from Sigma Chemical Company, USA. 
3.Reagents used in electrophoresis 
Acrylamide, riboflavin and amidoschwarz were purchased from 
E.Merck, Germany.Dimethyldichlorosilane and N,N,N'N' tetrameth-
ylethylenediamine (TEMED) were obtained from BDH, England.N,N' 
methylenebisacrylamide was a product of Koch-Light Laboratories, 
England. Ammonium persulfate, sucrose, glycerol and glacial acetic 
acid were purchased from BDH, India. Bromophenol blue and 
tris(hydroxymethyl) aminomethane were obtained from P.PH., Poland 
and Fluka, Switzerland respectively. 
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4. Other reagents 
Bilirubin (Lot No.37F-0564) was obtained from Sigma Chemical 
Company, USA. Sodium azide was obtained from Fluka,Switzerland. 
Blue dextran was the product of V. P.Chest Institutejndia. 
5. Miscellaneous 
Blood bank and Aminal house of J.N. Medical College, A.M.U. 
Aligarh were the source of human and sheep bloods respectively. 
Dialysis sacks of different flat widths were purchased from Sigma 
Chemical Company, USA. Millipore filters (Pore size 0A5[i and 25mm 
diameter) were obtained from Millipore Corporation, USA. Solid glass 
beads ( 5mm diameter) were obtained from Kimble Resistant Glass, 
USA. Standard buffer tablets of pH 4.0, 7.0 and 9.2 were purchased 
from Glaxo, India. All glass distilled water was used throughout this 
study. 
B. METHODS 
1. pH measurements 
Elico pH meter, model LI-10 T using Elico combined glass 
electrode, type CL51 with a least count of 0.05 pH unit was used for 
pH measurements. The standard buffers of pH 4.0, 7.0 and 9.2 were 
used for the calibration of pH meter in acidic, neutral and alkaline 
pH range respectively 
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2. Optical measurements 
A Shimadzu double beam spectrophotometer, model UV-150-02 
was used for the measurement of light absorption in visible as well 
as in ultraviolet region. The matched silica cells of 1.0 cm path length 
were used. Fluorescence measurements were performed on a Shimadzu 
spectrofluorometer, model RP-540, equipped with a recorder, modelDRS. 
3. Fluorescence measurements 
Fluorescence emission and excitation spectra were obtained in 
O.IM tis HCl buffer, pH 8.0. An excitation wavelength of 282 nm was 
fixed for recording the emission spectra of all the three preparations 
(BSA, HSA and SSA).The excitation spectra was obtained by fixing 
the emission wavelengths at 336 nm, 330 nm and 338 nm for BSA, 
HSA and SSA respectively. 
4. Determination of protein concentration 
The protein concentration was determined by one of the following 
methods, (i) ultra violet (uv) method and (ii) Method of Lowry 
et al,{\95\). 
(i) Ultra violet (uv) method 
Protein concentration in a given solution containing appropriate 
amount of protein was determined by reading absorbance at the X 
( 278 to 280 nm) of the protein using buffer or distilled water as blank. 
Protein concentration determination by UV method was restricted 
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to BSA and HSA by using specific extinction coefficient values of 
6.67 and 5.31( Janatova etal.,\96S, Edwards etal.,\969,) respectively. 
(ii) Method of Lowry et.al.,(1951) 
Two reagents namely copper reagent and folin phenol reagent 
were used in this method 
(a) Preparation of copper reagent 
For the preparation of copper reagent, three stock solutions were 
used; they were 4% sodium carbonate (w/v), 4% sodium potassium 
tartarate (w/v), 2% copper sulfate(w/v). They were mixed in a ratio 
of 100:1:1. The solution was filtered before use. 
(b) Preparation of Folin-phenol reagent 
This reagent was prepared according to the procedure given by 
Folin & Ciocalteu (1927). lOOgm of sodium tungstate, 25gm of sodium 
molybdate, 50ml of 85% orthophosphoric acid , 100ml of hydrochloric 
acid and 700ml of distilled water were mixed in a two litre round 
bottom flask, wrapped with black carbon paper to protect from light. 
The flask was shaken thoroughly , fitted with a double walled glass 
condenser and then the contents were refluxed for about ten hours. Then 
150gm of lithium sulfate , 50ml distilled water and a few drops of 
liquid bromine were added in refluxed mixture and boiled for thirty 
minutes without condenser to remove excess bromine. The total 
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volume of mixture was made upto one litre with distilled water 
after cooling. The Folin-phenol reagent thus prepared was stored in 
an amber colored bottle. The reagent was diluted to 1:4 with distilled 
water before use. 
(c) Procedure 
An appropriate volume of protein was taken and volume was made 
upto one millilitre with buffer or water. Then 5ml of copper reagent 
was added and mixed well. After ten minutes of incubation at room 
temperature, one millilitre of Folin-phenol reagent was added to each 
tube and mixed well. The color intensity was recorded at 700nm after 
half an hour on a double beam spectrophotometer using a blank solution 
which contained one millilitre buffer or water instead of protein solution. 
5. Gel chromatography 
Gel chromatography was performed on a sephacryl S-200 column 
(90 x 2.25 cm ).Sephacryl S-200HR was suspended in one litre of 
distilled water Then the fine particles were removed by washing the 
gel several times with distilled water. A column of uniform diameter 
was thoroughly cleaned with detergent, chromic acid and finally with 
water and mounted vertically in stand with the help of a clamp. The 
outlet of the column was connected with a small latex tubing attached 
with a screw stopcock to regulate the flow rate. The radius (r) of the 
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column was determined by measuring the volume (v) of a certain 
height(h) of liquid column at two different places. The relation 
used for the determination of radius (r) of column is: 
V = Tcr^ h (i) 
r = Vv/7ih (ii) 
Clean and boiled glass wool was placed at the bottom end of the column. 
The surface of glass wool was covered with a layer of glass beads. 
One third of the column was then filled with the operating buffer. Then 
whole gel slurry was poured into the column with the help of a glass 
rod. The gel was lef^  to settle under gravity over night at room temperature. 
The outlet was opened carefully at a flow rate of 5ml per hour. When 
the gel formed a smooth surface, the flow rate was increased gradually 
to a value approximately 1.5 times of the desired flow rate. The gel 
bed was stabilized by passing 0.06M sodium phosphate buffer, pH 
7.0 containing 0.02% sodium azide, which was three times of the total 
bed volume .By passing a band of 0.2% blue dextran 2000, the packing 
of the column was checked and the void volume( V )^ was obtained 
from the elution profile of blue dextran. For application of sample, 
the eluent buffer was first drained off. The sample was applied carefully 
with the help of an applicator. The sample size usually being 1.0 to 
1.5% of the total volume(Vt) of the column. The stopcock was then 
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opened slowly and the sample was allowed to pass down the upper 
gel surface. When all the protein solution had passed into the gel 
, an equal volume of buffer was applied and allowed to pass through 
the gel bed. The column was then connected with the buffer reservoir 
and the column flow rate was adjusted to the desired flow rate. Fractions 
of 2.0 to 5.0 millilitre were collected and monitored by the method 
of Lowry et al{\95\). 
6. Polyacrylamide gel electrophoresis 
Polyacrylamide gel electrophoresis was performed in tris-glycine 
buffer(0.025MtrisandO. 192Mglycine),pH8.2 on7,5%polyacrylamide 
gels according to the method of Davis(1964). The gel plates were 
washed with detergent, chromic acid and water and then dried. These 
plastic spacers were placed along the sides and the bottom of the plates. 
These plates were mounted in a vertical fashion. The sides of the 
plates were sealed with 1 %(w/v) agarose solution. Three fourth of the 
space between the plates was filled with resolving gel solution containing 
7.5% (w/v) acrylamide, 0.2%(w/v)N,N'-methylenebisacrylamide, 
0.08% (w/v) ammonium persulfate and 0.05%(v/v) 
N,N,N',N' tetramethylethylenediamine(TEMED). The solution was 
allowed to polymerize for 30 minutes at room temperature. Then the 
remaining space between the gel plates above the resolving gel was 
filled with stacking gel solution containing 3.6% (w/v) acrylamide, 
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0.096% (w/v) N,N'-methyIenebisacrylamide, 0.07% (w/v) ammonium 
persulfate and 0 08% (v/v) N,N,N',N' tetramethylenediamine. A comb 
was placed after pouring the stacking gel solution between the plates. 
Again it was left for polymerisation at room temperature for 30 minutes. 
The bottom bracket , the sides clamps and the plastic spacer at the 
botom were removed. The lower tank of the slab gel electrophoresis 
apparatus was filled with the electrophoretic buffer. Formation of 
bubbles was avoided . Sample containing 20ng of protein in lOfxl of 
the same buffer was applied in the well. Electrophoresis was carried 
out till the bromophenol blue front migrated to nearly 3/4 of the total 
length of the gel.Then the gel was taken out and stained with 0.1% 
(w/v) coomassie brilliant blue G-250 solution in water-methanol and 
acetic acid ( in the ratio of 5:5:2) for two hours. Destaining was 
performed firstly with 30% (v/v) methanol and 10% (v/v) glacial acetic 
acid and subsequent incubations wdth 7% (v/v) glacial acetic acid. 
7. Isolation of human and sheep serum albumins 
In a conical flask, hundred millilitre of human or sheep serum 
and 140.0 ml of 4.0 M ammonium sulfate solution (whose pH had 
been adjusted to 7.0 with ammonium hydroxide) were taken to make 
the serum 2.26M in ammonium sulfate. The mixture was centrifuged 
at 7000rpm for twenty minutes after twelve hours incubation at room 
temperature. Supernatant was diluted with frequent addition of 0.5N 
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sulphuric acid as well as water to make the final concentration of 
ammonium sulfate solution to 1.9M and pH to 4.2. The mixture was 
kept at room temperature for 12 hours and precipitate was collected 
by centrifugation at TOOOrpm for twenty minutes. The precipitate was 
washed three times with 2.2M ammonium sulfate solution pH 4.2 and 
then dissolved in 0.06M sodium phosphate buffer , pH 7.0. Dialysis 
was done against 0.06M sodium phosphate buffer, pH 7.0. 
The serum albumin thus obtained was further purified by column 
chromatography on Sephacryl S-200 HR column. 
8. Preparation of serum albumin monomer 
Pure BSA monomer was obtained by gel filtration of commercial 
BSA preparation (Sisco Research Laboratories Pvt. Ltd, India ) on a 
Sephacryl S-200 HR column, equilibrated with 0.06M sodium phosphate 
buffer, pH 7.0 containing 0.02% sodium azide . The monomeric BSA 
will henceforth be referred to as BSA. Monomeric form of HSA and 
SSA were obtained on S-200 HR column chromatography of isolated 
serum albumin preparations. 
9. Ultraviolet absorption spectroscopy 
The ultraviolet absorption spectra of BSA, HSA and SSA were 
recorded in 0.06M sodium phosphate buffer, pH 7.0 in the wavelength 
range 250-360 nm on a double beam spectrophotometer, model UV 
150-02.By extrapolation of the absorbance values from 360 to 330nm 
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in the absorption region, the absorbance values were corrected for 
scattering.The protein concentration was generally between l-2mg/ml. 
The absorbance values at different wavelengths were then converted 
into values of extinction coefficient.The ultraviolet absorption spectra 
of drugs i.e. indomethacin, chlorpromazine and oxyphenbutazone were 
also recorded. 
10. Interaction of bilirubin with serum albumins 
The interaction of bilirubin with serum albumins ( BSA, HSA 
and SSA) was studied by visible absorption spectroscopy and by 
fluorescence quenching titration method. 
(i) Visible absorption spectroscopy 
Bilirubin solution was prepared by dissolving 6.0mg of bilirubin 
crystals in 1.0ml of 1 .OM sodium carbonate solution containing 1 .OmM 
EDTA and the volume was made upto 10.0ml with 0.1M tris-HCl buffer, 
pH 8.0, 1=0.15. The bilirubin solution was prepared fresh just before 
use and kept at 4°C after filtration. The bottle was wrapped with black 
carbon paper to protect from photopolymerization. The concentration 
of bilirubin was determined by recording its absorbance at 440nm, 
employing a molar extinction coefficient of 47,500 ( Jacobsen & 
Wennberg, 1974). The absorption spectra of free bilirubin and complexes 
of bilirubin with albumins ( BSA, HSA and SSA ) were recorded 
at room temperature in the wavelength range 550-360nm. The complexes 
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of bilirubin and albumin were prepared in the molar ratios of 0.5, 1.0 
and 2.0. For each molar ratio, a separate blank was prepared which 
contained identical amount of bilirubin but no protein. The difference 
spectra were obtained mannually by substracting the absorbance of 
free bilirubin from that of bilirubin-albumin complex at each wavelength 
and plotting the difference in absorption against wavelength. At different 
ionic strengths, the interaction of bilirubin with albumins (BSA, HSA 
and SSA) was studied at a molar ratio of 1.0 and pH 8.0. In these 
experiments, 0.024M sodium phosphate buffer, pH 8.0 was used and 
desired ionic strength was achieved by adding requisite amount of 
sodium chloride. Respective blanks were prepared in the same way 
except that they were devoid of protein. Absorption spectra and 
difference absorption spectra were obtained as described above. 
The interaction of bilirubin with albumins ( BSA,HSA and SSA) 
at different pH values was also studied by visible absorption spectroscopy 
by using bilirubin-albumin molar ratio of 1.0. Bilirubin and albumin 
solutions were taken in equimolar amounts to obtain a molar ratio of 
one and buffer of different pH was added. Absorption spectra of bilirubin 
-albumin complexes were recorded in the wavelengths range of 550 
to 360nm. Respective blanks were prepared in the same way except 
that they were devoid of protein. Difference absorption spectra were 
obtained as described above. 
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(ii) Fluorescence quench titration method 
Fluorescence quench titration was carried out in tris-HCI buffer,pH 
8.0, 1=0.10 at 25°C. The protein concentration was S.OjxM for all the 
three preparations. To obtain varying molar ratios from 0.0 to 2.0 
between bilirubin and albumin increasing amounts of bilirubin were 
added to albumin solution. For all the three preparations, excitation 
wavelength was 282nm and emission spectra were recorded in the 
wavelength range of 300-400nm. Fluorescence intensity obtained was 
converted into relative fluorescence by taking the fluorescence intensity 
in the absence of bilirubin as 100. Finally, percent fluorescence 
quenching was calculated and it was plotted against bilirubin-albumin 
molar ratio. 
11. Interaction of drugs with albumins 
The interaction of drugs, namely, indomethacin, chlorpromazine 
and oxyphenbutazone with serum albumins (bovine, human and sheep) 
was studied by fluorescence quenching method. The single titration 
was performed in sodium phosphate buffer, pH 7.4 at 25°C. To a fixed 
amount of protein solution ( S^ iM) taken in a series of tubes, desired 
volume of stock drug solution was added to obtain different molar ratios 
of drug to albumin in the range of 0.0 to 4.0 and the final volume 
was made upto 5. 0ml with sodium phosphate buffer, pH 7.4. Fluorescence 
emission spectra were recorded in the wavelength range of 300-400nm 
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by exciting the protein solution at 282nm. The spectra were recorded 
exactly after ten minutes of the addition of drug solution. These binding 
studies were performed at varying ionic strengths and desired ionic 
strength was adjusted by adding the requisite amount of sodium chloride. 
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Isolation and characterization of human and sheep serum 
albumins 
Bovine, human and sheep serum albumins have been used in these 
studies. Human and sheep serum albumins were isolated from human 
and sheep sera respectively by a salt fractionation procedure developed 
in this laboratory ( Tayyab & Qasim,1990) and described in the ex-
perimental section, while bovine serum albumin was obtained from 
commercial source ( Sisco Research Laboratories, India). The elution 
profiles of HSA, SSA and BSA on Sephacryl S-200HR column are 
shown in Fig. 2 ( A, B and C). As can be seen from the figure, all 
three preparations eluted in a single symmetrical major peak. Elution 
profile of BSA was characterized by the presence of several fast eluting 
small peaks in addition to a major peak (Fig. IC). In all three 
preparations, the elution volume(Ve) to void volume(Vo) ratio of the 
major peak was identical within experimental error ( see Table III). 
The charge homogeneity in various albumin preparations was 
checked by polyacrylamide gel electrophoresis performed in 0.02M 
Tris-glycine buffer, pH 8.2 and the electrophoretic pattern is shown 
in Fig. 3. In all the three preparations, a single major band was obtained 
after staining the gels with coomassie blue R-250. The relative mobility 
values (Rm) of protein bands are depicted in Table III. Fluorescence 
excitation and emission spectra of BSA, HSA and SSA are shown in 
Figs. 4 and 5. All the three proteins gave an excitation maxima at 
282nm and emission maxima between 330 and 338nm. The results 
are depicted in Table III. 
JO poqjaLU sqj Xq pajojiuoiu puB pspsjjOD 3J3A\ JLUQ l jo 
SU0IJ3BJJ sqx jq/iui^l jo S^BJ A\oy B JB psjcjado SB.W uiuniOD 
sq) puB psqddB SBA\ Q7. H^ 'J^iJ^Q sjEqdsoqd lunipos jo 
luiQ I uiuisiojdJOsuiBjSqijuiusi (UID9/. i \ on)^HOOc'S 
iXjDBqdss uo 0)vs a PUB (a)VSS'(V) VSHjo ssjyojd uounja j-gy 
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TABLE-III 
Gel filtration, electrophoresis and fluorescence data for 
serum albumins 
Albumin 
preparation 
VeA/b Rm Excitation Emission 
maximum(nm) maximum(nm) 
Bovine serum 
albumin 
Human serum 
albumin 
Sheep serum 
albumin 
1.81 0.870 
1.83 0.862 
1.83 0.779 
282 
282 
282 
336 
330 
338 
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Fig. 3. Polyacrylamide gel electrophoretic pattern of BSA, HSA and 
SSA per formed in 0.02M tris-glycine buffer, pH 8.2. A current 
of 4mA/gel tube was applied for 4 hours. The gels were stained 
with 1% amidoschwarz and destained mechanically with 7% 
acetic acid. Various protein bands are BSA(l), HSA(2) and 
SSA(3) The arrow shows the positions of dye bands. 
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Fig.4. Fluorescence excitation spectra of BSA(A), HSA(B) and 
SSA(C) in 0.1M tris HCl buffer, pH 8.0. The excitation spectra 
were recorded at an emission wavelength of 336nm. 
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Fig. 5. Fluorescence emission spectra of BSA(A), HS A(B) and SSA(C) 
in O.IM tris HCl buffer, pH 8.0. The emission spectra were 
recorded at excitation wavelength of 282nm. 
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Bilirubin -albumin interaction 
The visible absorption spectra of bilirubin and bilirubin-albumin 
complexes are shown in Fig. 6. The absorption maxima of aqueous 
bilirubin solution occured at 435 nm. There was a red shift of about 
25nm in the absorption spectrum of bilirubin by the addition of equimolar 
amount of all albumin preparations as shown in Fig.6. The interaction 
of bilirubin with albumins (BSA, HSA and SSA) was studied at different 
molar ratios of bilirubin to albumin viz 0.5, 1.0 and 2.0. The visible 
difference spectra of complexes of bilirubin with BSA, HSA and SSA 
obtained at pH 8.0, I = 0.15 are shown in Figs. 7-9. The difference 
spectra were characterized by the presence of a positive peak at 480nm. 
The bilirubin binding was expressed in terms of difference spectral 
change at 480nm (AOD'°° at 480nm) and the results are shown in 
Table IV. 
The influence of ionic strength on the interaction of bilirubin with 
all the three preparations was studied by visible difference absorption 
spectroscopy. The visible difference spectra of bilirubin-albumin in-
teraction for all the three albumin preparations at bilirubin/albumin 
molar ratio of 1 1 and at five different ionic strengths viz. 0.02, 0.05, 
0.2, 0.5 and 1.0 are shown in Figs. 10-12. A plot of difference in 
absorption at 480nm versus ionic strength for BSA, HSA and SSA 
is shown in Fig. 13, and the binding data at different ionic strengths 
are summarized in TableV. 
The effect of pH on the interaction of bilirubin with all the three 
albumin preparations was studied by visible difference absorption 
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Fig.6. Absorption spectra of bilirubin in absence (0) and the presence 
of BSA (•), HSA (© ) and SSA( • ). These spectra were 
obtained in 0.1 M tris HCl buffer, pH 8.0, 1=0.15. Protein 
concentration was 8-15^M. 
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Fig.7. Visible difference absorption spectra of bilinibin-BSA com-
plex obtained in 0.1 M tris HCl buffer, pH 8.0, 1=0.15 at 
different molar ratios of bilirubin over albumin. The molar 
ratios were 0.5 (o), 1.0(A) and 2.0(«). The protein concen-
tration was 6.0nM. 
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Visible difference absorption spectra of bilirubin-HSA 
complex obtained in 0.1 M tris HCl buffer, pH 8.0, 1=0.15 
in different molar ratios ofbilinibin over albumin. The molar 
ratios were 0.5(o), 1.0(A) and 2.0(»). The protein concentra-
tion was 7.0 |iM. 
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Fig.9. Visible difference absorption spectra of bilirubin-SSA 
complex obtained in 0.1 M tns HCl buffer, pH 8.0, 1=0.15 
in different molar ratios of bilirubm over albumin. The 
molar ratios were 0.5(o), 1.0(A)and2(»). The protein con-
centration was 8 OjiM 
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TABLE -IV 
Comparative bilirubin binding data of seum albumins at 
different molar ratios (0.5, 1.0 and 2.0 ) 
Molar ratio ( B/A ) 
0.5 
1.0 
2.0 
BSA 
1.431 
2.109 
3.370 
AOD'°" 
at 480 nm 
HSA 
0.998 
1.996 
4.105 
SSA 
2.20 
3.69 
4.25 
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Visible difference absorption spectra of bilirubin-BSA com-
plex obtained at different ionic strength. The representation 
of different ionic strengths are 0 02(o).0 05(A), 0.2(A).0.5(«) 
and 1 0(*)The molar ratio of bilirubin over albumin was 
1.0. The spectra were recorded m 0 1M HQ\ butTer. pH 8 0. 
The protein concentration was i2 0^M 
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360 440 520 
Figl2-
Wavelength (nm) 
Visible difference absorption spectra of bilirubin-SSA 
complex obtained at different ionic strengths. The represen-
tation of ionic strengths are 0 02(o), 0 05(A), 0 2(«) , 0 5(A) 
and !()(•) The protein concentration was 15 0fiM and the 
molar artio of bilirubin o\er albumin was 10. 
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Fig.l3. Plot of AOD'"' 480nm of bilirubin-albumin complexes as 
a ftinction of ionic strengths.(o), (•) and (A) represent BSA, 
SSA and HS^ respectively. 
TABLE-V 
Comparative bilirubin binding data of serum albumins at 
different ionic strengths ( 0.02 to 1.0 ) 
Serum albumin 
Bovine serum albumin 
Human serum albumin 
Sheep serum albumin 
Ionic 
0.02 
0.05 
0.20 
0.50 
1.00 
0.02 
0.05 
0.20 
0.50 
1.00 
0.02 
0.05 
0.20 
0.50 
1.00 
strength 
at 480 nm 
3.516 
3.256 
3.004 
2.367 
1.913 
1.748 
1.642 
1.613 
1.661 
1.613 
3.845 
3.942 
3.468 
3.314 
2.927 
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spectroscopy. The difference spectra of bilirubin-albumin interaction 
for the three albumin preparations at bilirubin/albumin molar ratio of 
1:1 and at seven different pH values i.e. 8.0, 9.0, 10.0, 10.5, 11.0, 
11.5 and 12.0 are shovvn in Figs.14-16. Fig. 17 shows a plot of AOD'°° 
at 480nm versus pH values. 
Bilirubin binding to serum albumins (BSA, HSA and SSA) was 
also studied by fluorescence quenching technique. Addition of bilirubin 
to albumin caused severe quenching in its fluorescence spectra. The 
magnitude of quenching increased with the increase in bilirubin/al-
bumin molar ratio. The fluorescence quench titration of albumins with 
bilirubin was performed by taking a fixed concentration of protein in 
different test tubes and adding the increasing amounts of bilirubin. 
A molar ratio of 0.2 to 2.0 between bilirubin and albumin was obtained 
by the addition of increasing amounts of bilirubin. The emission spectra 
of all the three preparations obtained at ionic strength 0.15 and at 
different molar ratios is shown in Fig. 18. The percent fluorescence 
quenching was calculated at emission maxima in the same way as 
described in experimental section. The plots between percent fluores-
cence quenching and bilirubin albumin molar ratios are shown in 
Figs. 19-21. Table VI shows the values of relative fluorescence and 
percent quenching obtained at different bilirubin/albumin molar ratios 
for the three serum albumins. 
Drug-albumin interaction 
Binding of three different drugs, namely, indomethacin, 
chlorpromazine and oxyphenbutazone to two different serum albumins 
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Visible difference absorption spectra of bilirubin-BSA com-
plex obtained at different pH values The representation of 
different pH \alues are pH 8 0(o). 9 0(o). 10 0(A), 10 5(»), 
11.0(A). 115(») and 12 (^ (x^  The protein concentration was 
10 ()|.iM and the molar ratio of bilirubin o\er albumin was 
I () 
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Fig. 15. Visible difference absorption spectra of bilirubin-HSA com-
plex obtained at different pH values. The representation of 
different pH values are the same as in Fig. 14 except that 
pH 10.0(«) and pH10.5(A).The protein concentration was 
S.OfiM and the molar ratio of bilirubin over albumin was 
1.0. 
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Fig. 16. Visible difference absorption spectra of bilirubin-SSA 
complex obtained at different pH values. The representation 
of pH values are the same as in Fig. 15 except that pH 11.0(») 
and pH 11.5(A).The protein concentration was 7.0^M and 
the molar ratio of bilirubin over albumin was 1.0. 
58 
00 
Q 
6 
<i 
Fig. 17. Plot of AOD'*'° 480nm of bilirubin-albumin complexes as 
a function of pH values! o), (•) and (A) represent BSA, SSA 
and HSA respectively. 
59 
100.0 
300 350 300 350 300 
V/avelength (nm) 
350 
Fig. 18. Fluorescence emission spectra of BSA(A), HSA(B) and 
SSA(C) obtained m absence (1) and presence of (2 to 8) 
of bilirubin m 0 JmM tris HCl buffer pH 8.2. The molar 
ratios of bilirubin to albumin v\ere:(from top to bottom) 0, 
0 :. 0 4. 0 6. 0 8. 1 0. 15 and 2 0 The excitation wavelength 
was 282nm Ihc protein concentration was 5.0|iM. 
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Fig 19. Plot of percent quenching of BSA as a function of bilirubin-
albumin ratio. The spectra were obtained in 0.1M tris HCl 
buffer. pH 8.0. The protein concentration was lOO^M. 
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Fig.20. Plot of percent quenching of HSA as a ftmction of bilinibin-
albumin ratio. The protein concentration was lO.OnM. 
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Fig.21. Plot of percent quenching of SSA as a function of bilirubin-
albumin ratio. The protein concentration was IO.OJJM. 
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TABLE-Vl 
Comparative fluorescence quenching data of BSA, HSA and 
SSA 
Serum albumins 
BSA 
HSA 
SSA 
B/A ratio 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.50 
2.00 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.50 
2.00 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.50 
2.00 
Relative 
fluorescence 
100.00 
86.095 
74.665 
56.385 
43.809 
32.380 
20.950 
17.523 
100.00 
84.80 
68.80 
60.00 
50.56 
41.92 
29.60 
24.80 
100.00 
89.947 
77.998 
67.686 
62.398 
50.500 
32.785 
23.663 
% Quenching 
0.0 
13.905 
25334 
43.620 
56.191 
67.191 
79.050 
82.477 
0.0 
15.20 
31.20 
40.00 
49.44 
58.08 
70.40 
75.20 
0.0 
10.002 
22.002 
32.314 
37.602 
49.500 
67.214 
76.334 
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(BSA and SSA) was studied by fluorescence quenching technique as 
the addition of these drugs caused quenching in the fluorescence spectra 
of proteins. The fluorescence quench titration of different albumins, 
namely BSA and SSA with these drugs was performed at various ionic 
strengths (0.02, 0.15, 0.5 and 1.0). 
For bovine serum albumin, a molar ratio of 0.2 to 4.0 between 
drugs and albumin was obtained by taking a fixed concentration of 
protein and increasing volumes of drug solutions. Desired ionic strengths 
were obtained by the addition of requisite amount of sodium chloride. 
The fluorescence emission spectra of BSA in the absence and presence 
of increasing amounts of indomethacin (in the range of indomethacin/ 
BSA molar ratio of 0.2 to 4.0) at 0.02 ionic strengths, pH 7.4 are shown 
in Fig.22A. A significant increase in fluorescence quenching was 
observed on increasing the drug-albumin molar ratio. The fluorescence 
quench titration results of indomethacin-BSA interaction at three other 
ionic strengths viz. 0.15, 0.5 and 1.0 were qualitatively similar to the 
one obtained at 0.02 ionic strength. These results are shown in Fig.22 
B, C and D. However, they differ in the magnitude of the fluorescence 
quenching. This can be clearly seen when the fluorescence data were 
transformed into percent quenching and plotted against indomethacin-
albumin molar ratio ( see Figs.23 and 24) and the values are depicted 
in Table VII & VIII. 
Fig.25 A shows the fluorescence quench titration results of 
chlorpromazine-BSA interaction in sodium phosphate buffer, pH 7.4, 
1=0.02 and at 25^C. Like indomethacin, chJorpromazme also caused 
65 
100 h 
300 3^0 300 3^0 300 3A0 300 3A0 
Fig.22. Fluorescence emission spectra of BSA at different ionic 
strengths obtained in absence and presence of indomethacin. 
The molar ratios of indomethacin over albumin \Nere 0.0 to 
4.0( from top to bottom) and the representation of ionic 
strengths were 0 02(A), 0.15(B), 0.5(C) and 1.0(D). The 
protein concentration was 5.0|iM and excitation wavelength 
was 282nm. 
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Fig.23. Plot of percent quenching of BS A as a function of mdomethacin 
albumin ratio.(•) and (o) represent the ionic strength of 0.02 
and 0.15 respecti\el\. 
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O.A 1.2 
Clnd/ADrotio 
Fig. 24. Plot of percent quenching of BSA as a function of indomethacin-
albumin ratio.(») and (o) represent the ionic strength of 0.5 
and l.O respecti\ely. 
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TABLE VII 
Binding of indomethacin to BSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
2.0 
I -
Relative 
fluorescence 
100.00 
72.72 
57.57 
39.33 
21.21 
12.12 
9.09 
0.02 
% Q 
Ionic Strengths 
uenching 
0.0 
27.28 
42.43 
60.61 
78.79 
87.88 
90.91 
1 = 
Relative 
0.15 
% 
fluorescence 
100.00 
84.84 
71.20 
43.93 
33.33 
20.45 
15.15 
Quenching 
0.0 
15.16 
28.79 
56.06 
66.67 
79.55 
84.85 
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TABLE VIII 
Binding of indomethacin to BSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
91.40 
80.47 
56.25 
40.63 
29.06 
28.13 
Ionic Strengths 
0.50 
% Quenching 
0.0 
8.59 
19.53 
43.75 
59.38 
70.94 
71.87 
1 = 
Relative 
1.0 
% 
fluorescence 
100.00 
90.74 
83.82 
69.21 
61.52 
49.99 
49.21 
Quenching 
0.0 
9.25 
16.18 
30.79 
38.48 
40.02 
50.78 
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significant quenching in the fluorescence spectrum of BSA which 
increased on increasing the chlorpromazine-BSA molar ratio. Fig. 25 
B, C and D represents the fluorescence quench titration results of 
chlorpromazine-BSA interaction at ionic strengths 0.15, 0.50 and 1.0. 
These data were transformed into percent quenching and were plotted 
against chlorpromazine-BSA molar ratio (see Figs. 26 and 27). As can 
be seen from Figs.25 ( A, B, C and D), 26 and 27, the binding results 
differ markedly on changing the ionic strengths(see Table IX & X). 
The interaction of oxyphenbutazone was also studied with BSA 
by fluorescence quenching technique. The results are shown in Fig.28 
(A, B, C and D). These results were transformed into percent quenching 
and are represented in Figs. 29 and 30 and values are depicted in Table 
XI & XII. 
Drug binding studies with SSA were performed in the similar 
manner as that for BSA using fluorescence quenching titration method 
in sodium phosphate buffer, pH 7.4 and at different ionic strengths 
viz 0.02, 0.15, 0.50 and 1.0. Fluorescence quenching results of SSA 
obtained with indomethacin, chlorpromazine and oxyphenbutazone 
are shown in Figs.31-33. The transformed data in the form of percent 
quenching are represented in Figs.34-39(see Table XIEto XVIII). 
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O.A 1.2 
CChl/ADrotio 
Fig.26. Plot of percent quenching of BSA as a function of 
chlorpromazine-albumin ratio.(•) and (o) represent the ionic 
stength of 0.02 and 0.15 respectively. 
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OM 1.2 
CChl/ADrotio 
2.0 
Fig.27. Plot of percent quenching of BSA as a function of 
chlorpromazine-albumin ratio. (•) and (o) represent the ionic 
strength of 0.50 and 1.0 respectively. 
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TABLE IX 
Binding of chlorpromazine to BSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
95.44 
90.90 
80.81 
75.75 
72.11 
69.69 
Ionic Strengths 
0.02 
% Quenching 
0.0 
4.56 
9.10 
18.19 
24.25 
27.89 
30.31 
1 = 
Relative 
= 0.15 
% Quenching 
fluorescence 
100.00 
88.63 
84.84 
71.20 
64.24 
52.11 
51.51 
0.0 
11.38 
15.16 
28.80 
35.76 
47.88 
48.49 
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TABLE X 
Binding of chlorpromazine to BSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengtlis. 
Molar ratio 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
97.60 
87.29 
68.24 
58.72 
47.61 
42.85 
Ionic Strengths 
0.50 
% Quenching 
0.0 
2.40 
12.72 
31.76 
41.28 
52.39 
57.15 
1 = 
Relative 
1.0 
% 
fluorescence 
100.00 
74.99 
72.72 
62.11 
45.45 
36.36 
33.33 
Quenching 
0.0 
25.01 
27.28 
37,89 
54.55 
63.64 
66.67 
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100 -
5 0 -
3 00 3^0 300 3/rO 300 3A0 300 3^0 
Fig.28. Fluorescence emission spectra of BSA at different ionic 
strengths obtained in absence and presence of 
ox>phenbutazone.The molar ratio of ox>phenbutazone over 
albumin was 0.0 to 4.0 (from top to bottom) and the rep-
resentation of ionic strengths are 0.02(A), 0.05(B), 0.50(C) 
and 1.0(D). The protein concentration was 5.0|iM and ex-
citation wavelength was 282nm. 
77 
1.2 
COX/ADro t io 
Fig.29. Plot of percent quenching of BSA as a function of 
ox>phenbutazone-albumin ratio (•) and (o) represent the 
ionic strength of 0.02 and 0.15 respectively. 
kf ... 
" ^ -•. • . * < - " • — ' ' - • " ' ^•' . ' . - { S 
""M 
78 
1.2 
COX/ADrot io 
Fig.30. Plot of percent quenching of BSA as a function of 
oxyphenbutazone-albumin ratio.(#) and (o) represent the 
ionic strength of 0.50 and 1.0 respectively 
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TABLE XI 
Binding of oxyphenbutazone to BSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
89.39 
86.36 
68.17 
59.09 
51.51 
51.20 
Ionic Strengths 
0.02 
% Quenching 
0.0 
10.62 
13.64 
31.83 
40.91 
48.49 
48.79 
1 = 
Relative 
 0.15 
% 
fluorescence 
100.00 
87.87 
75.75 
60.60 
49.99 
42.42 
39.39 
Quenching 
0.0 
12.13 
24.25 
39.40 
50.00 
57.58 
60.61 
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TABLE XII 
Binding of oxyphenbutazone to BSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
86.36 
75.75 
59.09 
48.48 
39.38 
36.35 
Ionic Strengths 
0.50 
% Quenching 
0.0 
13.64 
24.25 
40.91 
51.52 
60.62 
63.64 
1 = 
Relative 
1.0 
% 
fluorescence 
100.00 
90.90 
75.75 
59.09 
46.21 
37.89 
36.32 
Quenching 
0.0 
9.1 
24.25 
40.91 
53.79 
62.12 
63.68 
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340 3A0 3/.0 340 
Fig.31. Fluorescence emission spectra of SSA at different ionic 
strengths obtained in the absence and presence of indomethacin. 
The molar ratio of indomethacin o\er albumin was 0.0 to 
2.0(from top to bottom) and the representation of ionic 
3t.engths are 0.02(A). 0.15(B), 0.50(C) and 1.0(D) The 
protein concentration was 5.0nM and excitation wavelength 
was 282rmi 
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3A0 3A0 3A0 3/;0 
Fig 32 Fluorescence emission spectra of SSA at difTerent ionic 
strengths obtained in the absence and presence of 
chlorpromazine. The molar ratio of chlorpromazine over 
albumin was 0 0 to 2 O(from top to bottom) and the repre-
sentation of ionic strengths arc 0 02(A). 0.15(B). 0 5(C) and 
1 0( D) The protein concentration was 5.0|.iM and excitation 
ua\elen2th was 282nm 
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100 
3A0 3A0 3A0 340 
Fig.33. Fluorescence emission spectra of SSA at different ionic 
strengths obtained in the absence and presence of 
ox>phenbutazone. The molar ratio of ox> phenbutazone o\er 
albumin was 0.0 to 2.0(from top to bottom) and the repre 
sentation of ionic strengths are 0.02(A), 0.15(B), 0.5(C) and 
1.0(D). The protein concentration was S.OmM and excitation 
wavelength was 282nm. 
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Fig. 34. Plot of percent quenching of S S A as a ftmction of indomethacin-
albumin ratio.(«) and (o) represent the ionic strength of 0.02 
and 0.15 respectively. 
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1.2 
CInd/ADrotio 
Fig 35. Plot of percent quenching of SS A as a function of indomethacin-
albumin ratio. (•) and (o) represent ionic strength of 0.50 
and 1.0 respectively. 
86 
1.2 
CChl/A3rQtio 
Fig.36. Plot of percent quenching of SSA as a function of 
chlorpromazine-albumin ratio, (o ) and (•) represent the ionic 
strength of 0.02 and 0.15 respectively. 
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0.4 V2 
CChl/Aarotio 
Fig.37. Plot of percent quenching of SSA as a function of 
chlorpromazine-albumin ratio.(o) and (•) represent the ionic 
strengths of 0.5 and 1.0 respectively. 
88 
1.2 
COX/AD rat io 
Fig.38 Plot of percent quenching of SSA as a function of 
oxyphenbutazone-albumin ratio (•) and (o) represent the 
ionic strength of 0.02 and 0.15 respectivel}. 
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OA 1.2 
C O X / A D r o t i o 
Fig.39. Plot of percent quenching of SSA as a function of 
ox>phenbutazone-albumin ratio, (o) and (•) represent the 
ionic strength of 0.50 and 1.0 respectively. 
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TABLE XIII 
Binding of indomethacin to SSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
98.50 
92.54 
91.04 
87.31 
83.58 
65.55 
56.72 
Ionic Strengths 
0.02 
% Quenching 
0.0 
1.50 
7.47 
8.95 
12.69 
16.42 
34.45 
43.29 
1 = 
Relative 
0.15 
% 
fluorescence 
100.00 
97.95 
94.57 
87.81 
87.81 
83.76 
66.19 
56.74 
Quenching 
0.0 
2.05 
5.43 
12.18 
12.18 
16.23 
33.80 
43.26 
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TABLE XIV 
Binding of indomethacin to SSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
99.37 
92.50 
91.25 
90.00 
83.75 
71.87 
53.11 
Ionic Strengths 
0.50 
% Quenching 
0.0 
0.63 
7.50 
8.75 
10.00 
16.25 
28.12 
46.87 
1 = 
Relative 
1.0 
% 
fluorescence 
100.00 
96.29 
91.35 
88.88 
88.88 
85.79 
72.83 
59.87 
Quenching 
0.0 
3.70 
8.65 
11.11 
11.11 
14.20 
27.16 
40.13 
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TABLE XV 
Binding of chlorpromazine to SSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
98.00 
97.35 
93.40 
90.11 
84.19 
72.35 
55.90 
Ionic Strengths 
0.02 
% Quenching 
0.0 
2.00 
2.65 
6.60 
9.89 
15.80 
27.64 
44.09 
1 = 
Relative 
0.15 
% 
fluorescence 
100.00 
99.28 
94.28 
89.99 
84.28 
82.85 
67.85 
59.99 
Quenching 
0.0 
0.72 
5.72 
10.00 
15.72 
17.15 
32.14 
40.10 
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TABLE XVI 
Binding of chlorpromazine to SSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
98.77 
96.39 
64.01 
92.82 
88.06 
70.91 
63.07 
Ionic 
0.50 
% 
Strengths 
Quenching 
0.0 
1.23 
3.61 
5.99 
7.18 
11.94 
29.09 
36.93 
1 = 
Relative 
1.0 
% 
fluorescence 
100.00 
95.32 
90.68 
87.19 
84.86 
84.86 
64.83 
58.13 
Quenching 
0.0 
4.67 
9.32 
12.81 
15.14 
15.14 
35.87 
41.87 
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TABLE XVII 
Binding of oxyphenbutazone to SSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
97.85 
92.85 
89.28 
87.85 
84.28 
71.43 
62.14 
Ionic Strengths 
0.02 
% Quenching 
0.0 
2.15 
7.15 
10.72 
12.15 
15.72 
28.58 
37.86 
1 = 
Relative 
= 0.15 
% 
fluorescence 
100.00 
94.39 
91.90 
86.94 
85.07 
80.11 
64.58 
55.89 
Quenching 
0.0 
5.60 
8.09 
13.06 
14.92 
19.89 
35.41 
44.11 
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TABLE XVIII 
Binding of oxyphenbutazone to SSA as studied by fluorescence 
quench titration at pH 7.4 and at different ionic strengths. 
Molar ratio 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 
1.0 
2.0 
1 = 
Relative 
fluorescence 
100.00 
95.63 
93.75 
92.50 
91.25 
90.00 
68.20 
63.12 
0.50 
% Q 
Ionic Strengths 
uenching 
0.0 
4.37 
6.25 
7.50 
8.75 
10.00 
31.79 
36.87 
1 = 
Relative 
1.0 
% 
fluorescence 
100.00 
95.25 
92.90 
89.37 
85.85 
82.30 
62.00 
54.09 
Quenching 
0.0 
4.75 
7.10 
10.63 
14.15 
17.68 
38.00 
45.90 
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red shift has also been reported by several workers(Sogami & Ogura, 1973; 
Brodersen,1979; Tayyab & Qasim,1987). When the binding was quan-
titated in terms of percent difference spectral change at 480nm( the 
wavelength at which the maximum change was observed), both BSA 
and HSA showed similar binding at bilirubin/albumin molar ratio of 
1:1, whereas SSA showed higher extent of binding as compared to 
HSA and BSA which may be due to the concentration difference in 
SSA preparation.This reflects that the primary bilirubin binding site 
on these albumins probably has the similar microenvironment. In view 
of the proposed involvement of salt bridge in bilirubin-albumin in-
teraction, the effect of ionic strength on the interaction of bilirubin 
with albumin preparations was studied by visible absorption difference 
spectroscopy The decrease in difference spectral change at 480nm 
with increase in ionic strength (Figs. 10-13) clearly suggests the im-
portance of electrostatic interactions in the binding of bilirubin to serum 
albumins. The effect was more pronounced in BSA and SSA than in 
HSA. This presumably means that electrostatic interactions between 
the carboxylate anions of bilirubin and positively charged groups 
contributed by Lys(or Arg) in the protein make greater contribution 
in this interaction in the former two albumins (BSA and SSA) than 
in HSA . In the primary structure of HSA and BSA, the region from 
residue 210 to 240 is believed to contain the critical lysine residue(Lys 
238 in BSA and Lys 240 in HSA) involved in salt bridge formation 
with the carbox>iate groups of bilirubin. To see the effect of pH on 
the interaction of bilirubin with serum albumins, study was performed 
98 
at different pH values ranging between 8.0 and 12.0. The binding was 
found to be unaffected between pH 8.0 & 11.0 in all the three albumins 
( Figs. 14-17). A sharp decrease in bilirubin binding above pH 11.0 
was presumably because of alkaline denaturation of albumin. The effect 
of pH on this interaction once again emphasizes that if a lysine residue 
is involved in this interaction then it must have an abnormally high 
pK value presumably greater than 11.0. This explanation fits nicely 
into earlier findings which have indicated that the critical lysine residue 
is buried in the protein interior (Tayyab & Qasim, 1987; Mir et a]., 1992; 
Trivedi et <af/.,unpublished work). Further, when the bilirubin binding 
to these albumins was checked by fluorescence quenching, all of them 
showed quenching in their emission spectra after the addition of 
bilirubin. The magnitude of quenching at a given bilirubin/albumin 
ratio was, within experimental error, identical to each other. From all 
the results of bilirubin-albumin interaction described above, it appears 
that the mechanism of interaction of bilirubin with sheep serum albumin 
is similar to those of bilirubin-BSA and bilirubin-HSA interaction. 
Serum albumin, a universal biocarrier binds a large number of 
exogenous compounds including drugs in addition to physiologically 
important ligands such as bilirubin, fatty acids etc. Out of these com-
pounds , some of them share a common binding site on albumin. In 
view of this, the binding of three drugs, namely, indomethacin, 
chlorpromazine and ox7phenbutazone was studied using fluorescence 
quenching as all these drugs produced significant quenching in the 
emission spectra of albumins upon their addition. In order to study 
99 
the role of electrostatic/hydrophobic interactions, the binding of these 
drugs to serum albumins(BSA and SSA) was studied at different ionic 
strengths ranging from 0.02 to 1.0. When the values of percent quench-
ing (representative of binding) obtained with indomethacin at drug/ 
albumin molar ratio of 1:1 were plotted against ionic strength, a 
significant decrease in binding was observed on increasing the ionic 
strength in both BSA and SSA (see Fig. 40). This decrease in binding 
of indomethacin to these albumins on increasing the ionic strength 
was suggestive of the involvement of electrostatic interactions in the 
binding process. Contrary to this, when the percent quenching data 
obtained with two other drugs i.e. chlorpromazine and oxyphenbutazone 
were plotted against ionic strength( Figs. 41-42) a significant increase 
in binding was noticed on increasing the ionic strength. This increase 
in binding on increasing the ionic strength was indicative of the 
importance of hydrophobic interactions in the binding of chlorpromazine 
and oxyphenbutazone to serum albumins. A comparison of the binding 
results of these drugs to BSA and SSA suggested that the extent of 
binding of these drugs was more pronounced in case of BSA as 
compared to SSA. The results of indomethacin-albumin interaction was 
also found to be similar to that of bilirubin-albumin interaction in terms 
of the involvement of electrostatic interactions. This was found to be 
in good agreement with the previous results that indomethacin shares 
the same binding site on albumin where the bilirubin binds(Brodersen 
et or/.,1983; Brodersen & Ebbessen,1983; (j)ie & Levy, 1979a, 1979b; 
Trivedi e/or/., unpublished work). Based on the results of chlorpromazine-
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albumin interaction obtained in this study and taking into consideration 
the previous reports on the bilirubin displacing effect of chlorpromazine, 
it seems more probable that the binding sites for these ligands on 
albumin are different and the drug displaces bilirubin in a noncom-
petitive or allosteric manner. Binding results of oxyphenbutazone to 
serum albumins also suggested that the drug binding site is different 
from bilirubin binding site. More studies are required to prove the 
occurrence of these sites on albumin molecule. 
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